MONMOUTH JUNCTION, N.J., March 7, 2017 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights planned activities at the 22nd International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2017) in San Diego, California, starting today through March 10, 2017. AKI & CRRT 2017 is one of the premier international conferences that covers blood purification in the intensive care unit and draws global participation from critical care nephrologists and intensivists worldwide.
Wednesday, March 8, 2017 – Regular Conference Agenda
12:30 – 2:00PM
Extracorporeal support for Multi-organ Failure: Emerging Strategies
Chair: Dr. Patrick Honoré, Brussels, Belgium
- Sorbents from Bench to Bedside
Dr. Claudio Ronco – Vincenza, Italy
- ECMO and CRRT
Dr. David Askenazi – Birmingham, USA
- Sorbent Based Therapy
Dr. John Kellum – Pittsburgh, USA
Thursday, March 09, 2017 – Company Sponsored Agenda
12:15 – 13:45 PM – Coronado Ballroom AB
Regain Control – Polymer based hemoadsorption in SIRS, Sepsis and Rhabdomyolysis
Chair: Dr. John Kellum and Prof. Dr. med. Steffen Mitzner
- The impact of hemoadsorption on cytokine removal and immune response
Dr. John Kellum, Pittsburgh, USA
- Safety and efficacy of hemoadsorption – Clinical experiences and evidence
Prof. Dr. med. Steffen Mitzner, Rostock, Germany
- New perspectives in the treatment of severe rhabdomyolysis
Dr. Jacques Duranteau, Paris, France
In addition, the company has been selected to present short poster presentations on the following submitted and accepted posters:
- A novel adsorbent system rapidly clears verapamil from human blood
- A novel adsorbent system rapidly clears amlodipine from human blood
- Broad adsorption of sepsis-related pathogen and damage-associated inflammatory mediators from whole blood using porous sorbent beads
Please visit the company at its exhibit booth (Booth #2), where representatives will discuss the role that CytoSorb plays in the treatment of a variety of conditions in the intensive care unit (ICU) such as sepsis, trauma, respiratory failure, liver failure, post-operative complications, severe acute pancreatitis, and many others.
About AKI & CRRT 2017
AKI & CRRT 2017 is intended to provide comprehensive coverage of the rapidly developing field of Critical Care Nephrology and Continuous Renal Replacement Therapy (CRRT). It will highlight the recent advances in the understanding of the pathophysiology of critical illness, acute kidney injury (AKI), emerging strategies in the management of sepsis, multi-organ failure, development and use of biomarkers, technical advances in CRRT, and the appropriate utilization of these techniques. The program presents exciting new developments and evidence for assessing critically-ill patients, pathophysiology of liver dysfunction and AKI using a mix of invited lectures, interactive workshops, tutorials, poster sessions and panel discussions.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 42 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) I trial – a multi-center, randomized controlled study that has demonstrated the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 20,000 human treatments to date.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 31 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Public Relations Contact:
SOURCE CytoSorbents Corporation